Title: Histone Deacetylase Inhibitor as a Novel Anticancer Agent: A Review
Abstract:Histone Deacetylase (HDAC) inhibitors are an exciting new class of drugs that are targeted as anti- cancer agents. These compounds can induce growth arrest, apoptosis and/ or terminal differentiation ...Histone Deacetylase (HDAC) inhibitors are an exciting new class of drugs that are targeted as anti- cancer agents. These compounds can induce growth arrest, apoptosis and/ or terminal differentiation in a variety of solid and hematological neoplasms in patients with advanced disease. Accumulation of acetylated histones in both normal and tumour cells can be used as a marker of biological activity. Hydroxamic acid based compounds are among the most promising HDAC inhibitors as potential anti-cancer drugs. There is still much to be understood about the family of HDACs, including the varying functions of different HDACs and the range of HDAC substrates. The development of selective HDAC inhibitors might be important in defining their biological role and potential as therapeutic agents. Clinically, the optimal dose, timing and duration of therapy, as well as the most appropriate agents to combine with HDAC inhibitors, are still to be defined.Read More
Publication Year: 2015
Publication Date: 2015-01-01
Language: en
Type: review
Access and Citation
Cited By Count: 2
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot